A Global, Open-Label, Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients
Lay Description
Category
- Heart, Vascular and Blood
- Lungs, Breathing and Bronchial
- IRB Number
- 20190423HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Rodolfo Estrada Anzueto
(210) 617-5256
estradaanzue@uthscsa.edu
Italia Herrera
(210) 567-2687
herrerai1@uthscsa.edu
Johnnie Jones
(210) 450-7277
jonesj21@uthscsa.edu
Deborah Levine
(210) 617-5256
levinedj@uthscsa.edu
Karl Mccloskey
mccloskeyk@uthscsa.edu
Lorannys Sanchez Tamarez
(210) 450-8332
sancheztamar@uthscsa.edu
Karl Mccloskey
mccloskeyk@uthscsa.edu
Rodolfo Estrada Anzueto
(210) 617-5256
estradaanzue@uthscsa.edu
Principal Investigator
Rodolfo Estrada Anzueto